HK Stock Market Move | HENLIUS (02696) rose by over 6% again. In the next four years, it will launch 8 new biotech drugs in the United States. Looking forward to subsequent overseas approvals and sales growth.

HENLIUS (02696) rose more than 6% again, rising 6.09% to 33.95 Hong Kong dollars at the time of publication, with a turnover of 32.7447 million Hong Kong dollars. On the news front, HENLIUS recently held the 2025 Global Research and Development Day. The company stated at the meeting that during the 2024 performance period, it had completed the submission of 25 marketing registration applications globally and obtained approval for 17 of them. As of now, HENLIUS has obtained marketing approval for 6 products in China and 4 products internationally, reaching more than 50 countries and regions. In the next four years, HENLIUS plans to promote the listing of 8 biologics in the United States, including products such as pembrolizumab and daratumumab. CMSC pointed out that HENLIUS' PD-1, pembrolizumab, rituximab, and bevacizumab have completed overseas expansion. In terms of future reserves, the biosimilar products pembrolizumab and daratumumab are being developed in cooperation with Organon, with pembrolizumab expected to be the first biosimilar drug approved in Europe and the United States. Daratumumab is also progressing well, with anticipation for subsequent overseas approvals and production ramp-up. Considering the potential value of the company's innovative pipeline and the potential for biosimilar drugs to go global, it is covered for the first time with a "strong buy" investment rating.